Future research will be needed to determine the precise molecular mechanisms through which MAPK4 agonists can shift immune responses in RA, including specific effects on B cell subpopulations, signaling pathways, and overall disease course and symptomatology. The gene discussed is MAPK4; the disease is rheumatoid arthritis.